MAGE基因在肾脏中的表达:MAGED2在肾损伤及应激小管细胞中上调
该研究通过多组学分析健康小鼠肾脏及实验性急性肾损伤(AKI)模型,发现五个MAGE基因在肾脏表达,且MAGED2在实验性AKI中显著上调。qRT-PCR、western blot和免疫组化验证了MAGED2在叶酸和顺铂诱导的AKI中mRNA和蛋白水平升高,并定位于小管细胞。培养小管细胞中血清剥夺和TWEAK可上调MAGED2,提示其在肾小管细胞损伤中可能起作用。
要点
- MAGED2在实验性和人类肾损伤的小管细胞中表达上调。
- 血清剥夺和TWEAK应激可上调培养小管细胞中MAGED2。
- MAGED2可能参与肾小管细胞损伤过程,需功能研究验证。
核心结论
- MAGED2在实验性和人类肾损伤的小管细胞中上调,并在培养小管细胞中由应激因素上调,提示其在肾小管细胞损伤中可能发挥作用。
研究设计与样本
- 利用系统生物学多组学(肾脏转录组学和蛋白质组学)分析健康成年小鼠肾脏及叶酸过量诱导的实验性急性肾损伤模型。
- 通过qRT-PCR、western blot和免疫组化验证肾毒性AKI中MAGED2表达变化。
- 在培养的小管细胞中研究调控基因表达的因素。
主要发现
- RNA-Seq显示五个MAGE基因(MAGED1、MAGED2、MAGED3、MAGEH1、MAGEE1)在健康成年小鼠肾脏mRNA水平表达。
- 微阵列转录组学显示MAGED2在实验性AKI中显著上调,肾脏蛋白质组学也发现MAGED2在AKI中上调。
- qRT-PCR和western blot分别证实叶酸和顺铂诱导的小鼠AKI中MAGED2 mRNA和蛋白表达增加。
- 免疫组化将MAGED2定位在实验性和人类肾损伤的小管细胞。
- 培养小管细胞中,血清剥夺和炎症细胞因子TWEAK上调MAGED2。
临床怎么用
- MAGED2可作为肾小管细胞损伤的潜在生物标志物,但需进一步功能研究验证其临床价值。
局限性
- 研究主要为表达和定位分析,未进行功能实验验证MAGED2在肾损伤中的具体作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mutations in Melanoma Antigen-encoding Gene D2 (MAGED2) promote tubular dysfunction, suggesting that MAGE proteins may play a role in kidney pathophysiology. We have characterized the expression and regulation of MAGE genes in normal kidneys and during kidney disease. METHODS: The expression of MAGE genes and their encoded proteins was explored by systems biology multi-omics (kidney transcriptomics and proteomics) in healthy adult murine kidneys and following induction of experimental acute kidney injury (AKI) by a folic acid overdose. Changes in kidney expression during nephrotoxic AKI were validated by quantitative reverse transcription-polymerase chain reaction (qRT-PCR), western blot and immunohistochemistry. Factors regulating gene expression were studied in cultured tubular cells. RESULTS: Five MAGE genes (MAGED1, MAGED2, MAGED3, MAGEH1, MAGEE1) were expressed at the mRNA level in healthy adult mouse kidneys, as assessed by RNA-Seq. Additionally, MAGED2 was significantly upregulated during experimental AKI as assessed by array transcriptomics. Kidney proteomics also identified MAGED2 as upregulated during AKI. The increased kidney expression of MAGED2 mRNA and protein was confirmed by qRT-PCR and western blot, respectively, in murine folic acid- and cisplatin-induced AKI. Immunohistochemistry located MAGED2 to tubular cells in experimental and human kidney injury. Tubular cell stressors [serum deprivation and the inflammatory cytokine tumour necrosis factor-like weak inducer of apoptosis (TWEAK)] upregulated MAGED2 in cultured tubular cells. CONCLUSIONS: MAGED2 is upregulated in tubular cells in experimental and human kidney injury and is increased by stressors in cultured tubular cells. This points to a role of MAGED2 in tubular cell injury during kidney disease that should be dissected by carefully designed functional approaches.
引用
- Valiño-Rivas L, Cuarental L, Agustin M, et al. MAGE genes in the kidney: identification of MAGED2 as upregulated during kidney injury and in stressed tubular cells. Nephrol Dial Transplant. 2019. PMID: 30541139. doi:10.1093/ndt/gfy367
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。